Day: March 10, 2021

HOUSTON, March 10, 2021 (GLOBE NEWSWIRE) — ION Geophysical Corporation (“ION” or the “Company”) (NYSE: IO) today announced it has commenced an offer to exchange (the “Exchange Offer”) any and all of its outstanding 9.125% Senior Secured Second Priority Notes due 2021 (the “Old Notes”) for its new 8.00% Senior Secured Second Priority Notes due 2025 (the “New Notes”) and the other consideration described below, upon the terms and subject to the conditions set forth in its prospectus dated today (the “Prospectus” and, together with the related letter of transmittal, the “Offering Materials”) and filed with the Securities and Exchange Commission (the “SEC”).The following table sets forth details regarding the Old Notes and the Exchange Consideration and the Early Participation Payment.The Exchange Offer will expire at 11:59 p.m., New...

IRVINE, Californie, 10 mars 2021 (GLOBE NEWSWIRE) — Lantronix Inc. (NASDAQ : LTRX), un fournisseur mondial de logiciels en tant que services (SaaS), de services de connectivité, de services d’ingénierie et de solutions matérielles intelligentes pour l’Internet des Objets (IdO) et la gestion des environnements distants (REM), a dévoilé aujourd’hui sa nouvelle EMG™7500, une passerelle de gestion périphérique sécurisée et rentable à petit facteur de forme. Conçue pour être utilisée dans pratiquement n’importe quel type de site distant ou sans effectif, l’EMG7500 fait partie intégrante de la solution de Lantronix pour la continuité des activités, qui associe matériel, logiciel et services à valeur ajoutée interconnectés. Avec l’EMG7500, Lantronix élargit son offre de solutions REM au sein de sa famille...

IRVINE, Kalifornien, March 10, 2021 (GLOBE NEWSWIRE) — Lantronix Inc. (NASDAQ: LTRX), ein globaler Anbieter von Software-as-a-Service (SaaS), Konnektivitätsdiensten, Engineering-Services, intelligenten Hardwarelösungen für das Internet der Dinge (IoT) und Remote Environment Management (REM), hat heute das neue EMG™7500 angekündigt, ein kostengünstiges, sicheres Edge-Management-Gateway in kleinem Format. Das EMG7500 ist für den Einsatz an praktisch allen Remote- oder unbemannten Standorten konzipiert und ein integrierter Bestandteil der Geschäftskontinuitätslösung von Lantronix, die Hardware, Software und Mehrwertdienste miteinander verzahnt. Mit dem EMG7500 erweitert Lantronix sein Angebot an REM-Lösungen innerhalb seiner EMG-Produktfamilie für Out-of-Band-Verwaltung (OOBM).„Lantronix ist ein führendes Unternehmen im Bereich Out-of-Band-Remote-Management...

CAMP HILL, Pa., March 10, 2021 (GLOBE NEWSWIRE) — Harsco Corporation (NYSE:HSC) (the “Company”) announced today that it amended its existing senior secured credit agreement by completing a new term loan B facility (the “New Term Loan”) of $500.0 million and extending the maturity of the existing $700.0 million revolving credit facility thereunder (the “Revolving Credit Facility”).The New Term Loan, which was over-subscribed, bears interest at a rate per annum of 2.25% over LIBOR, subject to a 0.50% floor. The New Term Loan has quarterly principal amortizations of .25% beginning in September 2021 and matures on March 10, 2028. The proceeds of the New Term Loan were applied to (a) repay in full the outstanding term loan A and term loan B under the Credit Facility, and (b) pay related transaction fees and expenses.At the same time,...

SAN FRANCISCO, March 10, 2021 (GLOBE NEWSWIRE) — Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted therapies for women’s cancers, today announced a poster presentation on OP-1250, a complete estrogen receptor (ER) antagonist (CERAN) and a selective ER degrader (SERD) being developed for the treatment of metastatic breast cancer and other women’s cancers, at the American Association for Cancer Research (AACR) Annual Meeting to be held virtually from April 10-15, 2021.The abstract of the poster was accepted by AACR as a late-breaking abstract and will be posted to the AACR online itinerary planner on April 9, 2021. Details of the poster presentation are as follows:Poster Title: The Complete Estrogen Receptor...

UTRECHT, The Netherlands and CAMBRIDGE, Mass., March 10, 2021 (GLOBE NEWSWIRE) — Merus N.V. (Nasdaq: MRUS) (“Merus”, “the Company”, “we”, or “our”), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today announced that Merus will present preclinical data from our zenocutuzumab and MCLA-129 programs in three poster presentations at the American Association for Cancer Research 2021 Annual Meeting being held virtually for two weeks, April 10-15, 2021 and May 17-21, 2021.E-Poster Presentation:Title: The HER2×HER3 bi-specific antibody zenocutuzumab is effective at blocking growth of tumors driven by NRG1 gene fusionsAbstract #: 956Session Category: Experimental and Molecular TherapeuticsSession Title: Biological Therapeutic AgentsTitle: Zenocutuzumab: An antibody...

CAMBRIDGE, Mass., March 10, 2021 (GLOBE NEWSWIRE) — TCR2 Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage immunotherapy company with a pipeline of novel T cell therapies for patients suffering from cancer, today announced that three e-poster presentations featuring new clinical data from the ongoing Phase 1 portion of the gavo-cel Phase 1/2 clinical trial for treatment refractory mesothelin-expressing solid tumors and preclinical data on its pipeline programs will be presented at the American Association for Cancer Research (AACR) Virtual Annual Meeting, taking place April 10-15, 2021.Abstracts can be found at www.aacr.org and include the following e-poster presentations below.Title: Preliminary Safety and Efficacy of gavocabtagene autoleucel (gavo-cel, TC-210), a T Cell Receptor Fusion Construct (TRuC®), in Patients with Treatment...

UTRECHT, Pays-Bas et CAMBRIDGE, Massachusetts, 10 mars 2021 (GLOBE NEWSWIRE) — Merus N.V. (Nasdaq : MRUS) (« Merus », « la Société », « nous », « notre » ou « nos »), une société d’oncologie de stade clinique qui développe des anticorps multispécifiques innovants et pleine longueur (Biclonics® et Triclonics), a annoncé aujourd’hui que Merus présentera les données précliniques de nos programmes Zenocutuzumab et MCLA-129 dans le cadre de trois présentations d’affiches lors de la réunion annuelle 2021 de l’American Association for Cancer Research, qui se tiendra au format virtuel sur deux semaines, du 10 au 15 avril 2021 et du 17 au 21 mai 2021.Présentation d’affiches électroniques :Titre : L’anticorps bi-spécifique HER2×HER3 Zenocutuzumab est efficace pour bloquer la croissance des tumeurs induites...

UTRECHT, Niederlande und CAMBRIDGE, Mass., March 10, 2021 (GLOBE NEWSWIRE) — Merus N.V.(Nasdaq: MRUS) („Merus“, „das Unternehmen“, „wir“ oder „unser“), ein Unternehmen aus dem Bereich der klinischen Onkologie, das innovative multispezifische volllange Antikörper (Biclonics® und Triclonics®) entwickelt, hat heute bekanntgegeben, dass es präklinische Daten seiner Zenocutuzumab- und MCLA-129-Programme in drei Poster-Präsentationen auf der Jahrestagung der American Association for Cancer Research 2021 präsentieren wird. Diese wird in virtueller Form über zwei Wochen vom 10. bis 15. April 2021 sowie vom 17. bis 21. Mai 2021 stattfinden.E-Poster-Präsentation:Titel: The HER2×HER3 bi-specific antibody zenocutuzumab is effective at blocking growth of tumors driven by NRG1 gene fusionsAbstract-Nr.: 956Kategorie der Session: Experimental and...

SHANGHAI, China, March 10, 2021 (GLOBE NEWSWIRE) — GDS Holdings Limited (“GDS Holdings”, “GDS” or the “Company”) (NASDAQ: GDS; HKEX: 9698), a leading developer and operator of high-performance data centers in China, today announced its unaudited financial results for the fourth quarter and full year ended December 31, 2020.Fourth Quarter 2020 Financial HighlightsNet revenue increased by 38.4% year-over-year (“Y-o-Y”) to RMB1,631.6 million (US$250.1 million) in the fourth quarter of 2020 (4Q2019: RMB1,179.2 million).Service revenue increased by 40.3% Y-o-Y to RMB1,627.5 million (US$249.4 million) in the fourth quarter of 2020 (4Q2019: RMB1,159.6 million).Net loss was RMB271.5 million (US$41.6 million) in the fourth quarter of 2020, compared with a net loss of RMB103.7 million in the fourth quarter of 2019.Adjusted EBITDA (non-GAAP)...